Paracchini Lara, D'Incalci Maurizio, Marchini Sergio
Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
Cancers (Basel). 2021 May 14;13(10):2386. doi: 10.3390/cancers13102386.
The lack of a sensitive and specific biomarker and the limits relating to the single primary tumor sampling make it difficult to monitor high-grade serous epithelial ovarian cancer (HGS-EOC) over time and to capture those alterations that are potentially useful in guiding clinical decisions. To overcome these issues, liquid biopsy has emerged as a very promising tool for HGS-EOC. The analysis of circulating tumor DNA appears to be feasible and studies assessing specific pathogenic mutations (i.e., ) or copy number alterations have shown a sufficient degree of sensitivity and specificity to be realistically used to monitor the effectiveness of antitumor therapy. Liquid biopsy can also provide potential important information on the mechanisms of sensitivity and resistance, e.g., by the determination of the reversion of mutations. Perspective studies are needed to test whether the application of liquid biopsy will significantly improve HGS-EOC management and patients' survival.
缺乏敏感且特异的生物标志物以及单次原发性肿瘤采样的局限性，使得难以长期监测高级别浆液性上皮性卵巢癌（HGS-EOC），也难以捕捉那些可能有助于指导临床决策的改变。为克服这些问题，液体活检已成为一种极有前景的HGS-EOC检测工具。循环肿瘤DNA分析似乎是可行的，评估特定致病突变（即 ）或拷贝数改变的研究已显示出足够的敏感性和特异性，可实际用于监测抗肿瘤治疗的效果。液体活检还可通过确定 突变的逆转等方式，提供有关敏感性和耐药性机制的潜在重要信息。需要开展前瞻性研究，以测试液体活检的应用是否会显著改善HGS-EOC的管理及患者生存率。
